Bank of Montreal Can Invests $305,000 in STAAR Surgical (NASDAQ:STAA)

Bank of Montreal Can purchased a new position in STAAR Surgical (NASDAQ:STAA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,783 shares of the medical instruments supplier’s stock, valued at approximately $305,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Evermay Wealth Management LLC boosted its holdings in shares of STAAR Surgical by 100.0% in the first quarter. Evermay Wealth Management LLC now owns 600 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 300 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of STAAR Surgical by 131.1% in the first quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 388 shares during the last quarter. UBS Group AG boosted its holdings in shares of STAAR Surgical by 130.7% in the second quarter. UBS Group AG now owns 805 shares of the medical instruments supplier’s stock worth $57,000 after buying an additional 456 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of STAAR Surgical by 348.4% in the second quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 641 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in shares of STAAR Surgical by 162.6% in the first quarter. Covestor Ltd now owns 1,111 shares of the medical instruments supplier’s stock worth $89,000 after buying an additional 688 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

STAA stock opened at $34.76 on Tuesday. STAAR Surgical has a one year low of $32.47 and a one year high of $81.81. The company’s fifty day moving average price is $39.43 and its 200-day moving average price is $47.76. The company has a market capitalization of $1.70 billion, a PE ratio of 89.13 and a beta of 1.05.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 20,144 shares of STAAR Surgical stock in a transaction that occurred on Tuesday, September 5th. The shares were bought at an average price of $41.87 per share, for a total transaction of $843,429.28. Following the completion of the transaction, the insider now owns 8,803,226 shares of the company’s stock, valued at approximately $368,591,072.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other STAAR Surgical news, Director Elizabeth Yeu Lin purchased 2,500 shares of STAAR Surgical stock in a transaction that occurred on Thursday, September 21st. The shares were bought at an average price of $40.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the director now owns 2,855 shares of the company’s stock, valued at approximately $114,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 20,144 shares of STAAR Surgical stock in a transaction that occurred on Tuesday, September 5th. The stock was acquired at an average price of $41.87 per share, for a total transaction of $843,429.28. Following the transaction, the insider now directly owns 8,803,226 shares of the company’s stock, valued at approximately $368,591,072.62. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 833,514 shares of company stock valued at $30,455,987. 1.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of research reports. Needham & Company LLC dropped their price objective on shares of STAAR Surgical from $52.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Stephens reaffirmed an “overweight” rating and set a $57.00 price target on shares of STAAR Surgical in a report on Monday, August 14th. Canaccord Genuity Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating and lowered their price target for the company from $77.00 to $48.00 in a report on Thursday, August 3rd. Stifel Nicolaus lowered their price target on shares of STAAR Surgical from $45.00 to $40.00 and set a “hold” rating on the stock in a report on Friday, September 22nd. Finally, Mizuho reaffirmed a “buy” rating and set a $65.00 price target on shares of STAAR Surgical in a report on Wednesday, September 13th. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $54.33.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.